PrediLife Partners With Institut Curie on Breast Cancer Risk

Industry news | 24 May, 2019 | CACLP

PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

MammoRisk — used in conjunction with mammograms — is designed to determine breast cancer risk using a patient's age, breast density, family history, and breast biopsy history, as well as a polygenic score based on the analysis of disease-linked genetic variations from a saliva sample.

Under the terms of their deal, the Institut Curie will perform MammoRisk genetic analyses, focusing on roughly 100 polymorphisms associated with increased breast cancer risk. The partners also intend to work together on future breast cancer-related research projects, Villejuif, France-based PrediLife said.

Additional terms were not disclosed.

"The collaboration underscores the ability of the Institut Curie's genomics platform to provide academic and industrial partners such as PrediLife with technological tools for high-throughput genomic analysis," David Gentien, head of the institute's genomics platform, said in a statement.

Filed under：

Press contact

CACLP - The largest IVD Expo & Conference

Back to list

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

Name *
Email *
Company name *
Country *

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Visit Exhibit Conferences Webinars Newsroom About Us FAQs

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

No, thanks. Yes, I agree.

Subscribe to CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.

Name *
Email *
Telephone
Job title
Company name *
Country *

By submitting the form here, you agree to our Privacy Policy and agree that we may store and access the information you provide.

Thank you for subscribing to CACLP News!

To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.

Go back

PrediLife Partners With Institut Curie on Breast Cancer Risk

Most popular

Mirxes Announces US$40M Synthetic Royalty-Backed Financing from CBC Group’s R-Bridge to Accelerate Global Growth

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

IVD China last week: Beckman Coulter and Health Genetech, Roche Diagnostics, Sansure Biotech, Canhelp Genomics

Werfen Receives US FDA 510(k) Clearance for Aptiva® Antiphospholipid Syndrome Reagents

bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip

Stay in touch with CACLP News

Subscribe to CACLP News

Thank you for subscribing to CACLP News!